EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

GLP-1 Receptor Agonists: A New Treatment in Parkinson’s Disease

Kallirhoe Kalinderi, Vasileios Papaliagkas iD, Liana Fidani

International Journal of Molecular Sciences · 29.03.2024 · 25 (7) · 3812

DOI: 10.3390/ijms25073812 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 29.03.2024. Verfasst von Kallirhoe Kalinderi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Medical Biology-Genetics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Gre…. Hauptthemen laut MEDLINE: Parkinson Disease, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 98-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Parkinson’s disease (PD) is one of the most common neurodegenerative diseases. Recent data highlight similarities between neurodegenerative diseases, including PD and type 2 diabetes mellitus (T2DM), suggesting a crucial interplay between the gut–brain axis. Glucagon-like peptide-1 receptor (GLP-1R) agonists, known for their use in T2DM treatment, are currently extensively studied as novel PD modifying agents. For this narrative review article, we searched PubMed and Scopus databases for peer-reviewed research, review articles and clinical trials regarding GLP-1R agonists and PD published in the English language with no time restrictions. We also screened the references of the selected articles for possible additional articles in order to include most of the key recent evidence. Many data on animal models and preclinical studies show that GLP1-R agonists can restore dopamine levels, inhibit dopaminergic loss, attenuate neuronal degeneration and alleviate motor and non-motor features of PD. Evidence from clinical studies is also very promising, enhancing the possibility of adding GLP1-R agonists to the current armamentarium of drugs available for PD treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseDiabetes Mellitus, Type 2AnimalsGlucagon-Like Peptide-1 Receptor AgonistsBrain-Gut AxisDatabases, FactualDopamine

Stichwörter der Autor:innen

GLP-1GLP1-R agonistsParkinson’s diseaseclinical trialsexendin-4liraglutidelixisenatideneurodegenerationsemaglutidetype 2 diabetes mellitus

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsDopamine

Autor:innen und Institutionen

  • Laboratory of Medical Biology-Genetics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
  • Department of Biomedical Sciences, School of Health Sciences, International Hellenic University, 57400 Thessaloniki, Greece.

ORCID-Profile: Vasileios Papaliagkas

Zitieren

APA

Kalinderi, K., Papaliagkas, V., & Fidani, L. (2024). GLP-1 Receptor Agonists: A New Treatment in Parkinson’s Disease. International Journal of Molecular Sciences, 25(7), 3812. https://doi.org/10.3390/ijms25073812

Vancouver

Kalinderi K, Papaliagkas V, Fidani L. GLP-1 Receptor Agonists: A New Treatment in Parkinson’s Disease. International Journal of Molecular Sciences. 2024;25(7):3812. doi:10.3390/ijms25073812

BibTeX
@article{Kalinderi2024,
  author = {Kalinderi, Kallirhoe and Papaliagkas, Vasileios and Fidani, Liana},
  title = {GLP-1 Receptor Agonists: A New Treatment in Parkinson’s Disease},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {7},
  pages = {3812},
  doi = {10.3390/ijms25073812}
}
Kostenlos starten →